Search results for: Competition
Filter search results
Biosimilar Competition: Lessons from Europe and Prospects for the US
1 October 2014
Based on an OHE lunchtime seminar by Professor Henry Grabowski, this seminar briefing explores the lessons learned from Europe’s experience with biosimilars, and provides an analysis of how the US…
What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
19 November 2024
…on-patent competition in the distribution of surplus. Furthermore, under IBP, the authors fail to take into consideration the potential benefits of IBP and CF in the form of increased competition:…
Spotlight on OHE: Making Health Care Choices and Decisions
7 January 2013
…incorporate competition in the provision of NHS-funded health care in England was the focus of the OHE Commission on Competition, which published its report in January 2012. OHE’s research and…
Two Economists Join OHE
10 March 2011
…of competition and regulation, and UK and EU competition law. Prior to the OHE, Arik was with the UK Competition Commission, where he was involved in a wide range of cases…
Biosimilars and Data Exclusivity
8 June 2010
…from 12.9 to 16.2 years for biologics, without competition from biosimilars. In estimating the potential effect of biosimilars on breakeven times and incentives for innovation, Prof Grabowski noted that price competition…
The Economics of Innovation in Times of Pandemic: How to Incentivise the Development, Supply, and Continuous Improvement of Innovative Solutions to Fight COVID-19?
22 May 2020
…and, how to keep competition going to incentivise the development and adoption of new improved versions of such solutions? There is no guarantee that we have a pathway to developing…
Victor R. Fuchs Award for 2020 Goes to Patricia Danzon
23 June 2020
…include: ‘Exits from Vaccine Markets in the US: The Role of Competition vs. Regulation’ (Danzon and Pereira, 2011); ‘Productivity in Pharmaceutical-Biotechnology R&D: The Role of Experience and Alliances’ (Danzon, Nicholson…
Canberra Hypothesis: the Economics of the Prescription Medicine Market
1 July 1975
The burden of this paper was that it was a fundamental misconception to believe that price competition was lacking in the prescription medicine market, at least in the context of…
Economic Evidence and NHS Reforms in England
19 January 2011
…created in 1991. For the first few years, the emphasis was on both price and quality competition; more recently, the focus has shifted to fixed prices, with competition based of…